The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
MRI is particularly valuable in pediatric care due to its non-invasive nature
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Subscribe To Our Newsletter & Stay Updated
